Expert Review of Anticancer Therapy
- Print ISSN
- Electronic ISSN
- Impact factor
- Usage rank
- Article count
- Free count
- Free percentage
- PDFs via platforms
- Ingenta, Gale, Expertreviews, and Rcgp
Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer.
We will elucidate developing therapies in non-muscle-invasive bladder cancer....
Current and emerging surveillance strategies to expand the window of opportunity for curative treatment after surgery in colorectal cancer.
Colorectal cancer is the third most common cancer globally. At diagnosis, more than 70% of patients have nonmetastatic disease. Cure rates for early-stage colorectal cancer have improved with primary screening, improvements in surgical techniques and advances in adjuvant chemotherapy. Despite optima...
Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.
I FL and selected cases of stage II, the administration of definitive involved field radiation usually results in long-lasting remission and is still considered the treatment of choice. For advanced disease (stages III-IV), the treating physician is called to select therapy from several options. Bec...
Breast cancer risk after exposure to fertility drugs.
In recent years, there has been an increase in the diagnosis of infertility. In industrialized countries, approximately 15% of couples experience this problem today, with a negative impact on quality of life. For this reason, assisted reproductive technologies and other treatments, finalized to over...
Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint.
Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel-based chemotherapy. Two agents (cabazitaxel and abiraterone) are already accessible to prescribers, havin...
Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition.
Approaches to treatment for many patients with advanced breast cancer are based on the expression of specific receptors. Treatments targeting the hormone receptor (typically the estrogen receptor) are used to reduce signaling through these receptors and thereby inhibit proliferation of breast cancer...
Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review.
Breast cancer remains the most common type of cancer affecting women worldwide with an estimated lifetime risk of 1:8. With developments in adjuvant treatment and the identification of breast cancer subtypes, rising expectation of 'personalized' and 'targeted' therapy, decisions on systemic therapy...
Immune reconstitution inflammatory syndrome in a large multicenter cohort study: case definition and comparability.
Evaluation of: Novak RM, Richardson JT, Buchacz K et al.; HIV Outpatient Study (HOPS) Investigators. Immune reconstitution inflammatory syndrome: incidence and implications for mortality. AIDS 26(6), 721-730 (2012). This study was nested within the HIV Outpatient Study cohort and investigated the i...
Plant essential oils and their constituents in coping with multidrug-resistant bacteria.
Antibiotic resistance is documented to be a serious problem that affects the choice of appropriate antibiotic therapy and increases the probability of unfavorable infection outcome. One of the proposed methods to cope with multidrug-resistant (MDR) bacteria is the use of alternative antibacterial tre...
Loss of miR-126 is crucial to pancreatic cancer progression.
The tumor-suppressor miRNA 126 (miR-126) is downregulated in many tumors and has recently been placed at the heart of complex metastatic pathways. Hamada and colleagues have identified miR-126 as being downregulated in pancreatic ductal adenocarcinoma (PDAC) patient samples and cell lines. The prote...